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Abstract
Purpose - The aim of this meta-analysis is to review the efficacy of atypical antipsychotics in
combination with clozapine. Previous meta-analysis have assessed the use of both typical and
atypical antipsychotics in combination with clozapine, combination treatment being withheld only
for those patients deemed treatment resistant.
Design/methodology/approach - We conducted the meta-analysis in accordance with the Pre-
ferred Reporting Items for Sytematic Reviews and Meta-Analyses (PRISMA) guidelines. The fol-
lowing inclusion criteria was applied; i.) Trials and reports that were written in English; ii.) An
antipsychotic was added to clozapine; ii.) The non-clozapine antipsychotic was atypical; iii.) Trials
were randomised, double-blind placebo controlled; iv.) Trials were conducted between the years
of 2000 and 2015
Findings - The effect sizes gained from analysis showed a small benefit of combination therapy
over clozapine monotherapy.
Research limitations/implications - The initial trial search unveiled 1,412 studies. After the in-
clusion and exclusion criteria was applied, 10 trials were used in this meta-analysis.
Practical implications - the recommendation of this analysis that alternative medications be
sought in order to treat patients who have a sub-optimal response to clozapine with a combi-
nation other than two second generation antipsychotics. This route should only be used once all
other treatment options have been exhausted
Originality/value - This work extends existing meta-analysis by incorporating data from more re-
cent trials.
Keywords Schizophrenia, Atypical, Antipsychotics, Combination, risperidone, aripiprazole
Paper type Research paper
Introduction
It is generally accepted that over the course of their lifetime, about 1% of the UK population will
develop schizophrenia, although one study suggests the true figure may be closer to 0.72% (Saha
et al., 2005). Furthermore, we should be clear as to the working definition of treatment resistant
schizophrenia as defined by Howes et al in their systematic review of randomized antipsychotic
clinical trials where definitions of treatment resistance were extracted (Howes et al., 2017).
Clozapine is an atypical antipsychotic reserved only for those patients who have been adequately
trialled unsuccessfully on at least two previous antipsychotics(NICE178, 2014). The failure is usu-
ally due to hematological side effects (Pirmohamed and Park, 1997). One of several side-effects
that can be attributed to non-clozapine atypical antipsychotics. A patient should be trialled on
clozapine for a minimum of 8-10 weeks before being classed as treatment resistant.
The term Treatment Resistant Schizophrenia was first coined by Kane et al (Kane et al., 1988),
where it was determined that those patients who have not responded to two previous antipsychotic
therapies should be given clozapine in doses equivalent of up 1000mg of chlorpromazine. The
benefits of clozapine include reduced risk of suicide (Meltzer et al., 2003) and overall mortality
(Sernyak et al., 2001) in schizophrenia. Antipsychotic polypharmacy in which more than one an-
tipsychotic drug is used to treat a patient‘s schizophrenia is becoming more common in practice
(Langan and Shajahan, 2010), however it is advised against due to the increased risk of side ef-
fects such as sedation, weight gain, extra-pyramidal side effects and blood disorders (Dold and
Leucht, 2014). It has been recommended by the National Institute of Clinical Excellence (NICE)
that combining antipsychotic medication should not be initiated unless it is to change one medi-
cation to another, even this should only be for a short period of time (NICE82, 2008). However,
despite the risks of polyphramacy, the basis for using clozapine is because of the association with
significant clinical improvement relative to usual treatment, along with reduced suicidal thoughts
and reduced rehospitalization rates.
The aim of this meta-analysis is to review the efficacy of atypical antipsychotics in combination
with clozapine.
Methods
This meta-analysis was devised in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). Databases searched in-
clude; Science Direct, PubMed, PubMed Central, Cochrane Library and the clinical trials register.
The search for material was updated in June 2017. Key terms used in the search were; clozapine,
augmentation, combination, treatment-resistant schizophrenia, refractory schizophrenia as well as
the generic names of all the atypical antipsychotics.
Inclusion criteria.
The following inclusion criteria was applied; i.) Trials and reports that were written in English; ii.)
An antipsychotic was added to clozapine; ii.) The non-clozapine antipsychotic was atypical; iii.)
Trials were randomised, double-blind placebo controlled; iv.) Trials were conducted between the
years of 2000 and 2015.
Exclusion criteria.
Trials were excluded on the basis; i.) Drugs were not in combination with clozapine but were a
comparison; ii.) Drugs were compared to each other and not a placebo; iii.) Trials were open and
single-blind; iv.) Case Reviews.
Statistical analysis.
Particular rating scales were used when developing the forest plots in order to obtain an effect size,
we used the random-effects model as we believed the different studies had different effect sizes.
The fixed-effect model assumes some heterogeneity of effect and that every study has a com-
mon true effect size, this cannot be assumed and the random-effects model is more appropriate
under these circumstances. The Positive and Negative Symptom Scale (PANSS) (Kay, Fiszbein
and Opler, 1987) and The Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962)
were used to assess the efficacy of the drugs on schizophrenia. Some papers used a mixture of
scales and some used only PANNS or BPRS, we used the method devised by Leucht to convert
between them (Leucht et al., 2013). The Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1989) and the Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen
et al., 1990) were used for the effect sizes of both negative and positive schizophrenic symptoms
respectively.
Cohen‘s D was used to assess the impact of the treatments (Ferguson, 2009), 0.2, 0.5 and 0.8
showing either a small, medium or large effect respectively. Confidence intervals and Standard-
ised Mean Deviations (SMD) were presented in the forest plots. A funnel plot and quantile-quantile
plot was also generated to assess publication bias of the trials included in the meta-analysis. Com-
parison of trials lasting < 10 weeks and >10 weeks were compared to assess the impact of trial
length on treatment efficacy as well as comparison of the same atypical agents.
The R statistical analysis software was used in conjunction with the RStudio Editor, the Metafor
package was used in the generation of the forest plots and the funnel plot using a random ef-
fects model. We used the Standardised Mean Difference, giving the meta-analysis the ability to
compare the outcome of all the trials together regardless of the rating scale. Forest plots were
generated in order to gain an overall effect size for the combination of the atypical antipsychotic
with clozapine in regards to overall symptoms.
Results
The initial search revealed 1,412 studies, after the inclusion and exclusion criteria was applied, a
total of 10 studies with 588 patients (age range 18-65, average 35.3, 378 males and 210 females)
were included. Randomised controlled trials included four atypical antipsychotics combined with
clozapine, sertindole (n=1), olanzapine (n=1), aripiprazole (n=3) and risperidone (n=5) against a
placebo. Trial characteristics used are given in figure 1.
The effect size (95% Confidence Intervals) in figure 1 for the impact of treatment on overall
symptoms was -0.30 [-0.57, -0.02], for the impact of treatment on negative symptoms was -0.18
[-0.46, 0.11] in figure 3 and the impact of treatment on positive symptoms was -0.25 [-0.81, 0.30]
in figure 4. The funnel plot, figure 2 and the quantile-quantile plot in figure 3 showed no obvious
publication bias.
The standardised mean differences for overall change in BPRS/PANSS, negative and positive
symptoms found were of small improvement, -0.19, -0.18 and -0.25 respectively. This showed
that the combination of clozapine with a second generation antipsychotic, seen in figure 1, 2 and
3 showed a small improvement in patient‘s symptoms. So far this is the only meta-analysis to
look solely at the efficacy of second generation antipsychotics combined with clozapine. Previous
analyses (Taylor et al., 2012) looked at the combination of both typical and atypical antipsychotics
with clozapine treatment. Similar to this study, an effect size of 0.239, showed small effect of co-
therapy over monotherapy. Comparison of effect sizes of both first and patient symptomatology
showed there is no distinct difference between the efficacy of either class of drugs.
A systematic review (Correll et al., 2009) assessed antipsychotic combinations of first and second
generation antipsychotics including clozapine as a part of the combination against monotherapy
in schizophrenia. This study showed that antipsychotic combination therapy was favourable com-
pared to the control. In all the studies patients had been diagnosed using DSM-IV, and had been
trialled, unsuccessfully on two or more previous antipsychotics before the initiation of clozapine.
4.1 Overall change in BPRS/PANSS
The forest plot in figure 1 was generated using a random effects model. It can be seen from the
effect size that only two trials (Muscatello et al., 2011) and (Fleischhacker et al., 2010) completely
favored co-therapy compared to the other trials in our study.
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Figure 1: Forest plot indicating effect of each trial and overall outcome using a random effects
model
The forest plot in figure 1, indicates the standardised mean differences (SMD) for the individual
outcomes of each trial, the black diamond indicates the overall SMD for the meta-analysis (-0.30),
this effect size indicates a small favour of cotherapy. Examining the results from previous meta-
analyses in this area and systematic reviews, the value does not differ greatly (Taylor et al., 2012)
and (Taylor and Smith, 2009), indicating that overall the combination of antipsychotics, which is
often used in clinical practice, is only of small effect (Correll et al., 2009).
Figure 2 displays a funnel plot which is intended to highlight publication bias, larger studies with
higher power are placed towards the top and lower powered studies are placed near the bottom.
The funnel plot, is generally symmetrical with three trials outside the funnel triangle (Fleischacker,
Honer and Yagcioglu) indicating heterogeneity but not necessarily publication bias.
Common flaws in treatment during trials which may affect bias shown in the funnel plot in-
clude; failure in randomization, poor blinding or large number of patients which are lost through
follow up (Taylor and Smith, 2009). The heterogeneity of this meta-analysis was moderate-to-high
(I2= 61.82%) variability within the trials, using a random effects model. The full statistics output for
the analysis is given below:
Random-Effects Model (k = 10; τ2 estimator: Random Effects)τ2 (estimated amount of total heterogeneity): 0.1120 (SE = 0.0896)
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Figure 2: Funnel plot for the random effects model, indicating heterogeneity for some studies
τ (square root of estimated τ2 value): 0.3346I2 (total heterogeneity / total variability): 62.11%H2 (total variability / sampling variability): 2.64
Test for Heterogeneity:
Q(df = 9) = 25.3604, p-val = 0.0026
Where: τ is the between studies standard deviation and τ2 is the between studies variance of
the true effect sizes, I2 is the ratio of true heterogeneity to total observed variation, H2 is the is
the square root of the chi-square heterogeneity statistic divided by its degrees of freedom, Q is
Cochran’s statistic for estimating a measure of weighted squared deviations. Interpreting the val-
ues for I2 are usually low at 25%, moderate at 50% and high at 75% based on work by Higgins
(Higgins et al., 2003).
We investigated these potential problems further by plotting a quantile-quantile diagram, the stud-
ies should lie on the diagonal line with slope of 1, going through the (0,0) point. Deviations from
this may indicate that (a) the (residual) heterogeneity in the true effects is non-normally distributed,
(b) there are subgroups in the data that are not adequately modeled, and/or (c) that publication
bias is present. We observe that the most of the studies are close the the diagonal and the three
studies outside the original funnel plot are well within the confidence intervals.
4.2 Trials with aripiprazole
For the trials where aripiprazole combinations were used both groups showed favour of combi-
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Figure 3: quantile-quantile plot of study heterogeneity
nation therapy. (Muscatello et al., 2011) Only one trial showed significant change in effects size
compared to all trials within this meta-analysis. This could be due to several factors; a)patients
may have been stabilised longer on clozapine although have partial response to the drug, b)longer
trial length (24 weeks) c) Higher aripiprazole dose. Patients in this trial were allowed to take Lo-
razepam 5mg/day for insomnia or agitation. This may not have been acceptable in the other trials
in this meta-analysis. However patients did not receive any antidepressants or anticonvulsants
two months prior to this trial.
Aripiprazole augmentation in the second trial (Chang et al., 2008) had an effect size of -0.12,
which implied a small change in the rating scale used, however in the conclusion of the study
it was stated there was no improvement to overall BPRS rating however had a larger effect on
patient‘s negative symptoms. In comparison to Muscatello, the study lasted only 8 weeks. This
may have potentially affected the outcome of the trial even though it has been stated that 6 weeks
is sufficient enough time for a patient to be treated with an antipsychotic. The study by Fleis-
chhacker was included our analysis, (Fleischhacker et al., 2010) this work investigated the effect
of combined aripiprazole and clozapine on the weight in patients. PANSS was measured in pa-
tients as a secondary outcome, this availed no effect in the forms of clinical efficacy. Primary
outcomes of this trial included mean change in body weight from baseline to week 16. From the
primary outcome, aripiprazole-treated patients also showed a statistically significant difference in
weight loss as well as a reduction in BMI, total and low-density lipoprotein. As weight gain and
susceptibility of metabolic disorders increases when a patient is taking clozapine, the outcome of
this trial is beneficial for patients.
Aripiprazole has a slightly different mechanism of action compared to other atypical antipsychotics.
It is a partial D2 and 5-HT2 agonist which means it does not bind fully to the receptor. Clozapine
binds to several receptors, D1-D5 and 5-HT2, as well as other receptors. Due to aripiprazole not
fully binding to the receptor site, it is not competing with clozapine for that site and it is not causing
the molecules to dissociate. The slight difference in the receptor profiles of these two drugs indi-
cates why both trials had an effect size in preference of the combination treatment.
4.3 Trials with risperidone
In the trials where risperidone was combined with clozapine, it can be seen none of effect sizes
of these trials is as significant as Muscatello‘s (Muscatello et al., 2011). Two trials (Weiner et al.,
2010) and (Freudenreich et al., 2007) showed favour of the clozapine and risperidone combina-
tion. However, compared to the other two studies (Honer et al., 2006) and (Yagcioglu et al., 2005)
where monotherapy was favoured there was no difference in the dose of the add-on drug which
was 4mg/day. Therefore it is with difficulty to say where the changes in efficacy have arisen from.
Randomised, controlled trials involving risperidone lasted a range of 6-16 weeks. Trials which
lasted less than ten weeks did not show efficacy for the combinations used. risperidone, like
clozapine, is an antagonist at both D2 and 5-HT2 receptor sites (Golan et al., 2007). Both drugs
are competing for the same sites to bind to, this indicates why only some trials may have had an
effect size in favour of co-therapy.
The problems with risperidone may have arisen where the patients had previously been trialled
on this drug and were deemed unresponsive, or the patient was unable to tolerate the combina-
tions. Another factor which may have affected trial outcome, was the sample size. Those with the
diagnosis of schizophrenia may respond to a first or a second generation anti-psychotic without
ever having to be treated with clozapine which is reserved for patients deemed to have refractory
schizophrenia. Therefore, those patients who are treated with clozapine is a smaller sample than
those who may have responded to prior treatment. This indicates that unless a multicentre trial,
large sample sizes in randomised controlled trials where patients are treated with clozapine may
be very difficult to find.
4.4 Trial with Olanzapine
The study undertaken by Constantine involved randomly switching the co-therapy patients to a
clozapine + placebo, leaving the other patients to a clozapine+olanzapine therapy (Constantine
et al., 2015). The initial motivation for this trial was to overcome certain polypharmacy issues in-
volved with the treatment of schizophrenia. The followup investigation was longer than most trials
and at the end of 360 days the patients PANNS score was more or less stable. The trial tended to
suggest that those who stayed on co-therapy had better outcomes, while those who switched to
clozapine alone appeared to have a n increase in positive symptoms
4.5 Trial with Sertindole
The study by Nielsen using a combination of clozapine and sertindole did not improve or worsen
their cognitive functions, they discuss that sample size may be an issue but admit their studies
results are comparative to the other studies (Nielsen et al., 2012) Their choice of sertindole was
motivated by it’s low levels of sedation and seemed therefore an ideal cotherapy. However, after
the 12 week trial was over, the results did not indicate any correlation between cognitive function
and psychopathology as highlighted by the PANNS and GAF and CGI scores.
4.6 Trials lasting longer than 10 weeks and Trials shorter than 10 weeks.
Work by Taylor compared trials of less than 10 weeks in length to those longer than 10 weeks. A
meta-regression plot was produced in order to see the relationship between the effect size and trial
length (Taylor et al., 2012). Randomised controlled trials lasting longer than ten weeks showed a
marginal increase in effect size (-0.223) when compared to those less than ten weeks in length
(-0.103). This indicates that for a trial where clozapine is combined with a second drug, a longer
trial, ideally ≥10 weeks, this coincides with guidance (NICE178, 2014) recommending a trial of
combination treatment to last at least 8-10 weeks. This will allow patients to become accustomed
to adhering to two different medications.
When comparing studies which lasted longer than 10 weeks (Muscatello et al., 2011) and (Weiner
et al., 2010) it was possible to see a larger effect size when compared to those of a shorter dura-
tion. Both trials lasting long than ten weeks exhibited an effect size larger than -0.19, this indicates
that the efficacy of the trials ranged from moderate to large. Effect size may have been affected if
sample size was smaller than 30, or if the trial was biased in any way. Barbui et al (Barbui et al.,
2009) found within the systematic review the effect size of none blinded trials was larger than the
trials where double blinding was involved.
Studies that lasted less than 10 weeks varied in their favour of combination therapy over monother-
apy. Two studies (Chang et al., 2008) and (Freudenreich et al., 2007) showed favor of combination
treatment over monotherapy. Monotherapy was favoured in the other two studies (Honer et al.,
2006) and (Yagcioglu et al., 2005). Again this may have been due to several factors; firstly, the
patient may not have responded to the medication. Secondly, the patient may have been non-
adherent or have a problem with compliance. Thirdly, the patient may have insufficient clozapine
levels due to taking a second atypical antipsychotic.
4.9 Limitations
There are several limitations to this meta-analysis including the small number of patients recruited
to several of the trials. The mean sample size of the trials was 69.2 (range 24-204, median 56),
trials of less than 30 participants do not reflect well in effect size calculations due to the small
range of results. This is likely to give the trial less power to change or show any significance, small
trials are likely to be more biased via giving a larger effect than large multicentre studies.
Another limitation of the analysis is the small number of trials conducted using atypical antipsy-
chotics in combination with clozapine for treatment resistant patients. Only studies including arip-
iprazole (3), sertindole (1), olanzapine (1) and risperidone (5) could be analysed.
This analysis looks at the efficacy of a second generation antipsychotic drug combined with cloza-
pine for patients with refractory schizophrenia. Other therapies have been used to treat refractory
schizophrenia with either some or little improvement in patient‘s symptoms. These include; ECT,
CBT, combinations with different classes of drugs; mood stabilisers and antidepressants. It was
not possible nor appropriate to include such studies into our analysis
Conclusions
The treatment of refractory schizophrenia is a common activity for mental health professionals.
Schizophrenia places demands on and adversely effects the quality of life, social aspects and the
patients ability to work. It is often a disorder that is associated with co-morbidities. Buckley found
that co-morbidities such as substance abuse, anxiety, depression, panic disorder, post-traumatic
stress disorder and obsessive compulsive disorder were highly prevalent among schizophrenic
patients (Buckley et al., 2009). These have further effects upon the patient from medication to
quality of life (Dold and Leucht, 2014).
Other factors to consider in regards to combination treatments, is the possible increased risk of
adverse reactions when combining two drugs from the same class. All second generation antipsy-
chotics come with an increased risk of weight gain and metabolic side effects. The only exception
to this was (Fleischhacker et al., 2010) where the addition of aripiprazole to clozapine reduced
weight, BMI and lipid profile in patients. Finally, it has been found through statistical techniques
that combination of a second generation antipsychotic with clozapine, the gold-standard treatment
for schizophrenia, is only marginally beneficial. The therapy may show some improvement within
individual patients however, the overview of the therapy as a whole, is not beneficial for the group.
Therefore, it is the recommendation of this analysis that alternative medications be sought in order
to treat patients who have a sub-optimal response to clozapine with a combination other than two
second generation antipsychotics. This route should only be used once all other treatment options
have been exhausted.
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